# Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform Neurofibromas

> **NCT02177825** · PHASE2 · TERMINATED · sponsor: **St. Justine's Hospital** · enrollment: 5 (actual)

## Conditions studied

- Plexiform Neurofibromas

## Interventions

- **DRUG:** Imatinib Mesylate

## Key facts

- **NCT ID:** NCT02177825
- **Lead sponsor:** St. Justine's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-06
- **Primary completion:** 2019-03-01
- **Final completion:** 2019-03-01
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Slow accrual 5 patients out of 25 expected. Primary objectives could not be met without recruiting more patients.
- **Last updated:** 2019-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02177825

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02177825, "Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform Neurofibromas". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02177825. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*